Voluntary nationwide recall: Sucralfate (Nostrum – July)

Jul. 2025Pharmacy Updates

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.

Nostrum Labs filed bankruptcy on Sept. 30, 2024. In connection with that filing, the company has ceased and shut down operations. Nostrum Labs is initiating a voluntary recall of Sucralfate Tablets USP 1 gram, all lots within expiry, as a result of the closures and discontinuation of its quality activities. This recall pertains only to Sucralfate Tablets USP 1 gram manufactured by Nostrum Labs after June 2023. No other Nostrum Labs products are affected by this recall. Using a product that may not meet quality standards means that the company is unable to confirm that the product has the correct identity, strength, quality, and purity characteristics.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Sucralfate, you should talk to your doctor before stopping the medication.

As of July 11, 2025, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates